Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy

References

• Hajjar I, Kotchen TA. Trends in the prevalence, awareness, treatment, and control of hypertension in the United States, 1988--2000. JAMA 2003;290:199-206
   PubMed Web of Science ®Google Scholar
• Fields LE, Burr VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001;14:286-92
   PubMed Web of Science ®Google Scholar
• Kulkarni SP, Alexander KP, Lyde B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151:185-91
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al., for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet 2003;361:1060]. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Mancia G, de Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension – The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Cifkova R, Erdine S, Fagard R, et al., for the ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-86
   PubMedGoogle Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
   PubMed Web of Science ®Google Scholar
• Weber MA. Creating a combination antihypertensive regimen: what does the research show? J Clin Hypertens (Greenwich) 2003;5:12-20
   PubMedGoogle Scholar
• Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep 2002;4:278-85
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501
   PubMed Web of Science ®Google Scholar
• Malacco E, Vari N, Capuano V, et al. A randomised, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765-80
   PubMed Web of Science ®Google Scholar
• Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) 2004;6:621-29
   PubMedGoogle Scholar
• Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810
   PubMed Web of Science ®Google Scholar
• Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-89
   PubMed Web of Science ®Google Scholar
• Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18:720-30
   PubMed Web of Science ®Google Scholar
• Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: impact of hypertension subtype, stage, age, and sex. Am Heart J 2003;145:888-95
   PubMed Web of Science ®Google Scholar
• Cheung BMY, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich) 2006;8:93-8
   PubMedGoogle Scholar
• Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005;28:385-407
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004;363:2049-51
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-34
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P, et al., for CAMELOT Investigators. Effects of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-26
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R, et al. for Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens 2004;22:847-57
   Google Scholar
• Kjeldsen SE, Aksnes TA, de la Sierra A, et al. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 2007;4:31-40
   Google Scholar
• Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005;25:1213-29
   PubMed Web of Science ®Google Scholar
• Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004;24:366-78
   PubMed Web of Science ®Google Scholar
• Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-α production after cardiac ischemia. J Cardiovasc Pharmacol 2006;47:636-42
   PubMed Web of Science ®Google Scholar
• Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 2004;35:348-50
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomised, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-64
   PubMedGoogle Scholar
• Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomised, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80
   PubMed Web of Science ®Google Scholar
• Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens (Greenwich) 2008;10:1-10
   Web of Science ®Google Scholar